S&P Futures
5,886.50 -19.50 (-0.33%) Dow Futures
43,427.00 -91.00 (-0.21%) Nasdaq Futures
20,359.00 -124.50 (-0.61%) Russell 2000 Futures
2,282.90 -8.30 (-0.36%) Crude Oil
70.80 +1.58 (+2.28%) Gold
2,751.30 +21.30 (+0.78%)
Lobe Sciences Ltd. (LOBE.CN)
- Business Wire
Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™
VANCOUVER, British Columbia, October 16, 2024--Lobe Sciences Ltd ("Lobe" or the "Company") (CSE: LOBE), (OTCQB: LOBEF), a biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Enclave Capital and Peak Asset Management (the "Bankers") to begin the process of raising funds to advance the development of the Company’s patented innovative pharmaceutical candidate, Conjugated Psilocin™. Lobe previously
- Business Wire
Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
VANCOUVER, British Columbia & STUART, Fla., October 02, 2024--Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma ("Alera or Alera Pharma"), biopharmaceutical companies focused on developing products to treat diseases with significant unmet medical needs, today announce the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent number 12,102,616 titled "Psilocin Mucate". As previously announced, Lobe Sciences will assign t
